Amid an ongoing struggle to vaccinate all above 18, Bharat Biotech was on Tuesday recommended by an expert panel to send its COVID-19 vaccine ‘Covaxin’ for phase II and phase III clinical trial on children between the age of two and 18 years. An approval to vaccinate the younger population would be a major breakthrough as it would mean reopening of schools and normal classes.#FightAgainstCorona #Coronavirus #Coronvirushavoc #CoronacaseInIndia #OxygenCrisis